Efficiency of Olopatadine Hydrochloride 0.1% in the Treatment of Vernal Keratoconjunctivitis and Goblet Cell Density

Corum, Isik; Yeniad, Barış; Bilgin, Lale Közer; Ilhan, Ridvan

doi:10.1089/jop.2005.21.400

Cited by 28 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Olopatadine hydrochloride 0.1% e/d were used along with steroids in patients and proved beneficial for long term treatment. Corum et al reported that 2 months treatment with olopatadine hydrochloride 0.1% relieves the signs and symptoms of VKC 10 .…”

Section: Discussionmentioning

confidence: 99%

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Nagrale¹

2017

jmscr

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Nagrale¹

2017

jmscr

View full text Add to dashboard Cite

“…However, both drugs were efficient and safe relieving the main symptoms and signs of VKC, including itching, tearing, conjunctival hyperemia, mucous discharge and photophobia. Olopatadine hydrochloride 0.1% was effective for relieving the signs and symptoms of VKC and reducing the number of goblet cells during treatment [30]. …”

Section: Management Of Vkcmentioning

confidence: 99%

Management of Vernal Keratoconjunctivitis

Leonardi

2013

Ophthalmol Ther

130

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. Affecting mainly children and young adults, it is an IgE- and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte and structural cell activation are involved. Treatment of VKC requires a multiple approach that includes conservative measures and pharmacologic treatment. Patients and parents should be made aware of the long duration of disease, its chronic evolution and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement. Mast cell stabilizers and antihistamines have been proven to be effective for the treatment of mild to moderate forms of VKC. In the most severe cases, topical steroids can be used as rescue medication to reduce conjunctival and corneal inflammation. Immunomodulators that have been investigated for VKC treatment include topical ocular preparations of cyclosporine A and tacrolimus. Topical cyclosporine A has been proven to be effective in the long-term treatment of VKC, significantly improving signs and symptoms without significant side effects.

show abstract

“…Activated eosinophils are known to increase MUC5AC expression [43] and, therefore, could contribute to the mucus discharge observed in these patients. Following topical anti-allergic and anti-inflammatory treatments in VKC patients, there are reductions in conjunctival goblet cell number and MUC5AC expression towards normal levels [44,45]. …”

Section: Alteration Of Mucins In Ocular Surface Diseasementioning

confidence: 99%

Functions of ocular surface mucins in health and disease

Mantelli

Argüeso²

2008

Current Opinion in Allergy &Amp; Clinical Immunology

286

245

View full text Add to dashboard Cite

Purpose of review-The purpose of the present review is to describe new concepts on the role of mucins in the protection of corneal and conjunctival epithelia and to identify alterations of mucins in ocular surface diseases.Recent findings-New evidence indicates that gel-forming and cell surface-associated mucins contribute differently to the protection of the ocular surface against allergens, pathogens, extracellular molecules, abrasive stress, and drying.Summary-Mucins are high molecular weight glycoproteins characterized by their extensive Oglycosylation. Major mucins expressed by the ocular surface epithelia include cell surface-associated mucins MUC1, -4 and -16, and the gel-forming mucin MUC5AC. Recent advances using functional assays have allowed the examination of their roles in the protection of corneal and conjunctival epithelia. Alterations in mucin and mucin O-glycan biosynthesis in ocular surface disorders, including allergy, non-autoimmune dry eye, autoimmune dry eye, and infection, are presented.

show abstract

Efficiency of Olopatadine Hydrochloride 0.1% in the Treatment of Vernal Keratoconjunctivitis and Goblet Cell Density

Abstract: Olopatadine hydrochloride 0.1% is an effective agent for relieving the signs and symptoms of vernal keratoconjunctivitis. Also, it reduces the number of goblet cells, which, in turn, decreases the amount of mucus discharge in vernal keratoconjunctivitis during treatment.

Cited by 28 publications

References 19 publications

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Management of Vernal Keratoconjunctivitis

Functions of ocular surface mucins in health and disease

Contact Info

Product

Resources

About